Free Daily Technical Summary Reports on Tandem Diabetes Care and Three Other Medical Supplies Stocks

Stock Research Monitor: OSUR, RMD, and COO

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TNDM sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com revisits the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. Under evaluation this morning are these four stocks: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), Tandem Diabetes Care Inc. (NASDAQ: TNDM), and The Cooper Cos. Inc. (NYSE: COO). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

OraSure Technologies

On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 507,436 shares. The stock ended at $17.41, declining slightly by 0.68% from the last trading session. The Company’s shares have gained 13.42% in the last month and 13.05% over the past year. The stock is trading above its 50-day moving average by 4.02%. Furthermore, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 59.25. Get the full research report on OSUR for free by clicking below at:

www.wallstequities.com/registration/?symbol=OSUR

ResMed

San Diego, California headquartered ResMed Inc.’s stock finished yesterday’s session 0.70% lower at $105.91 with a total trading volume of 420,256 shares. The Company’s shares have gained 8.26% in the last month, 8.50% over the previous three months, and 44.45% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.66% and 18.44%, respectively. Furthermore, shares of ResMed, which develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases, have an RSI of 67.21.

On May 29th, 2018, ResMed announced that it has entered into a definitive agreement to acquire privately held HEALTHCAREfirst, a provider of software solutions and services for home health and hospice agencies. The transaction’s financial terms were not disclosed, but it will not be material to ResMed’s consolidated financial results. The free technical report on RMD can be accessed at:

www.wallstequities.com/registration/?symbol=RMD

Tandem Diabetes Care

At the close of trading on Thursday, shares in San Diego, California headquartered Tandem Diabetes Care Inc. saw a decline of 2.13%, ending the day at $15.64. The stock recorded a trading volume of 1.57 million shares. The Company’s shares have surged 77.73% in the last month, 286.17% in the previous three months, and 97.42% over the past year. The stock is trading 69.34% and 201.32% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 75.82.

On May 14th, 2018, research firm Piper Jaffray upgraded the Company’s stock rating from ‘Neutral’ to ‘Overweight’. Sign up for free on Wall St. Equities and claim the latest report on TNDM at:

www.wallstequities.com/registration/?symbol=TNDM

Cooper

Pleasanton, California headquartered The Cooper Cos. Inc.’s shares ended the day 1.06% lower at $226.50. A total volume of 525,647 shares was traded, which was above their three months average volume of 431,500 shares. The stock is trading 0.24% below its 50-day moving average. Additionally, shares of Cooper, which operates as a medical device company worldwide, have an RSI of 47.40.

On May 21st, 2018, Cooper announced that it will present at the Goldman Sachs Healthcare Conference on June 14th, 2018, in Rancho Palos Verdes, California. Daniel G. McBride, Esq, Executive Vice President, COO, and President of CooperVision, Inc., will represent the Company in a presentation that is scheduled to begin at 12:20 p.m. ET that day. A live audio webcast of the presentation will be available under the Investor Relations section of the Company’s website. See the free research coverage on COO at:

www.wallstequities.com/registration/?symbol=COO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 502103